JENBURKT PHARMACEUTICALS LTD.
Buy, Hold or Sell?

Let's analyse JENBURKT PHARMACEUTICALS LTD. together

Penke I guess you are interested in JENBURKT PHARMACEUTICALS LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of JENBURKT PHARMACEUTICALS LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about JENBURKT PHARMACEUTICALS LTD.

I send you an email if I find something interesting about JENBURKT PHARMACEUTICALS LTD..

Quick analysis of JENBURKT PHARMACEUTICALS LTD. (30 sec.)

What can you expect buying and holding a share of JENBURKT PHARMACEUTICALS LTD.? (30 sec.)

How much money do you get?

INR0.00

When do you have the money?

1 year

How often do you get paid?

0.0%

What is your share worth?

Current worth

INR295.49

Expected worth in 1 year

INR342.96

How sure are you?

100.0%

+ What do you gain per year?

Total Gains per Share

INR47.47

Return On Investment

5.9%

For what price can you sell your share?

Current Price per Share

INR801.25

Expected price per share

INR660.05 - INR836.60

How sure are you?

50%

1. Valuation of JENBURKT PHARMACEUTICALS LTD. (5 min.)

Live pricePrice per Share (EOD)

INR801.25

Book Value per Share

INR295.49

2. Growth of JENBURKT PHARMACEUTICALS LTD. (5 min.)

Is JENBURKT PHARMACEUTICALS LTD. growing?

	Current year	Previous year	Grow	Grow %
How rich?	$15.6m	$14.5m	$641.8k	4.2%

How much money is JENBURKT PHARMACEUTICALS LTD. making?

	Current year	Previous year	Grow	Grow %
Making money	$820.5k	$618.3k	$202.2k	24.6%
Net Profit Margin	18.7%	15.7%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of JENBURKT PHARMACEUTICALS LTD. (5 min.)

What can you expect buying and holding a share of JENBURKT PHARMACEUTICALS LTD.? (5 min.)

Welcome investor! JENBURKT PHARMACEUTICALS LTD.'s management wants to use your money to grow the business. In return you get a share of JENBURKT PHARMACEUTICALS LTD..

What can you expect buying and holding a share of JENBURKT PHARMACEUTICALS LTD.?

First you should know what it really means to hold a share of JENBURKT PHARMACEUTICALS LTD.. And how you can make/lose money.

Speculation

The Price per Share of JENBURKT PHARMACEUTICALS LTD. is INR801.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of JENBURKT PHARMACEUTICALS LTD..
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in JENBURKT PHARMACEUTICALS LTD., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR295.49. Based on the TTM, the Book Value Change Per Share is INR11.87 per quarter. Based on the YOY, the Book Value Change Per Share is INR18.90 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of JENBURKT PHARMACEUTICALS LTD..

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	INR	% of Price per Share	INR	% of Price per Share	INR	% of Price per Share	INR	% of Price per Share	INR	% of Price per Share
Usd Eps	0.20	0.0%	0.19	0.0%	0.13	0.0%	0.17	0.0%	0.17	0.0%
Usd Book Value Change Per Share	0.22	0.0%	0.14	0.0%	0.23	0.0%	0.71	0.1%	0.71	0.1%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	0.22	0.0%	0.14	0.0%	0.23	0.0%	0.71	0.1%	0.71	0.1%
Usd Price Per Share	8.40	-	8.20	-	6.66	-	7.10	-	7.10	-
Price to Earnings Ratio	10.55	-	11.06	-	13.98	-	11.40	-	11.40	-
Price-to-Total Gains Ratio	38.55	-	79.09	-	30.00	-	44.05	-	44.05	-
Price to Book Ratio	2.37	-	2.39	-	2.11	-	2.21	-	2.21	-
Price-to-Total Gains Ratio	38.55	-	79.09	-	30.00	-	44.05	-	44.05	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	9.615
Number of shares	104

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	0.14	0.71
Usd Total Gains Per Share	0.14	0.71
Gains per Quarter (104 shares)	14.81	73.75
Gains per Year (104 shares)	59.24	295.02

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	59	49	0	295	285
2	0	118	108	0	590	580
3	0	178	167	0	885	875
4	0	237	226	0	1180	1170
5	0	296	285	0	1475	1465
6	0	355	344	0	1770	1760
7	0	415	403	0	2065	2055
8	0	474	462	0	2360	2350
9	0	533	521	0	2655	2645
10	0	592	580	0	2950	2940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	2.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%
Book Value Change Per Share	2.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%
Dividend per Share	0.0	0.0	2.0	0.0%	0.0	0.0	5.0	0.0%	0.0	0.0	5.0	0.0%	0.0	0.0	5.0	0.0%	0.0	0.0	5.0	0.0%
Total Gains per Share	2.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%	5.0	0.0	0.0	100.0%

Fundamentals of JENBURKT PHARMACEUTICALS LTD.

About JENBURKT PHARMACEUTICALS LTD.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.

1.1. Profitability of JENBURKT PHARMACEUTICALS LTD..

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit JENBURKT PHARMACEUTICALS LTD. earns for each ₹1 of revenue.

Above 10% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
A Net Profit Margin of 19.1% means that ₹0.19 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 19.1%. The company is making a huge profit. +2
The TTM is 18.7%. The company is making a huge profit. +2

Trends

Current period		Compared to		+/-
MRQ	19.1%	TTM	18.7%	+0.4%
TTM	18.7%	YOY	15.7%	+3.0%
TTM	18.7%	5Y	18.3%	+0.5%
5Y	18.3%	10Y	18.3%	0.0%

Measures how much net profit JENBURKT PHARMACEUTICALS LTD. earns for each ₹1 of revenue.

Revenue is the amount of profit JENBURKT PHARMACEUTICALS LTD. generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you ₹3. The company does not earn ₹3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is ₹1.5.

The ₹3 you pay for a cup of coffee is called revenue.
The ₹1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit JENBURKT PHARMACEUTICALS LTD. earns for each ₹1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
Can be used to compare companies within the industry.

You typically want a high profit margin. This means that for each ₹1 in sales, JENBURKT PHARMACEUTICALS LTD. makes more profit. This shows the investor how efficiently JENBURKT PHARMACEUTICALS LTD. is operating in general and compared to other companies in the same industry. JENBURKT PHARMACEUTICALS LTD. operates in the industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of JENBURKT PHARMACEUTICALS LTD.. If profit margins remain low (compared to the industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of JENBURKT PHARMACEUTICALS LTD. is 0.19. This means that JENBURKT PHARMACEUTICALS LTD. earned ₹0.19 for each ₹1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare JENBURKT PHARMACEUTICALS LTD. with other companies in the same industry ().
Net profit margin should rise over the years.
Can be influenced when JENBURKT PHARMACEUTICALS LTD. sells assets (profit will increase while costs remain the same).
It won’t show what part of JENBURKT PHARMACEUTICALS LTD. is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ JENBURKT PHARMACEUTICALS LTD. = 54,044
Total revenue MRQ JENBURKT PHARMACEUTICALS LTD. = 356,598
₹54,044 / ₹356,598 = 0.19 or 19.1%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient JENBURKT PHARMACEUTICALS LTD. is using its assets to generate profit.

Above 5% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
4.9% Return on Assets means that JENBURKT PHARMACEUTICALS LTD. generated ₹0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 4.9%. Using its assets, the company is less efficient in making profit.
The TTM is 4.7%. Using its assets, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	4.9%	TTM	4.7%	+0.2%
TTM	4.7%	YOY	3.6%	+1.1%
TTM	4.7%	5Y	4.5%	+0.2%
5Y	4.5%	10Y	4.5%	0.0%

Shows how efficient JENBURKT PHARMACEUTICALS LTD. is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively JENBURKT PHARMACEUTICALS LTD. is using its resources to generate profit. If the return on assets (4.9%) from JENBURKT PHARMACEUTICALS LTD. are higher than the mean () that means JENBURKT PHARMACEUTICALS LTD. is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of JENBURKT PHARMACEUTICALS LTD. is 4.9%. This means the company generated ₹0.05 for each ₹1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from JENBURKT PHARMACEUTICALS LTD. = 54,044
Total assets MRQ (balance sheet) from JENBURKT PHARMACEUTICALS LTD. = 1,499,201
54,044 / 1,499,201 = 0.05 or 4.9%

ROA is an important ratio as it will tell you how effectively JENBURKT PHARMACEUTICALS LTD. is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient JENBURKT PHARMACEUTICALS LTD. is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
5.6% Return on Equity means JENBURKT PHARMACEUTICALS LTD. generated ₹0.06 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 5.6%. Using its investors money, the company is less efficient in making profit.
The TTM is 5.4%. Using its investors money, the company is less efficient in making profit.

Trends

Current period		Compared to		+/-
MRQ	5.6%	TTM	5.4%	+0.2%
TTM	5.4%	YOY	4.2%	+1.2%
TTM	5.4%	5Y	5.3%	+0.1%
5Y	5.3%	10Y	5.3%	0.0%

Shows how efficient JENBURKT PHARMACEUTICALS LTD. is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of JENBURKT PHARMACEUTICALS LTD. is 5.6%. This means JENBURKT PHARMACEUTICALS LTD. generated ₹0.06 for each ₹1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if JENBURKT PHARMACEUTICALS LTD. existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) JENBURKT PHARMACEUTICALS LTD. = 54,044
Shareholders equity (balance sheet) MRQ JENBURKT PHARMACEUTICALS LTD. = 1,304,078
54,044 / 1,304,078 = 0.06 or 5.6%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of JENBURKT PHARMACEUTICALS LTD..

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient JENBURKT PHARMACEUTICALS LTD. is operating .

Measures how much profit JENBURKT PHARMACEUTICALS LTD. makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
An Operating Margin of 0.0% means the company generated ₹0.00 for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 0.0%. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.0%
TTM	-	YOY	-	0.0%
TTM	-	5Y	-	0.0%
5Y	-	10Y	-	0.0%

Measures how efficient JENBURKT PHARMACEUTICALS LTD. is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit JENBURKT PHARMACEUTICALS LTD. is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of JENBURKT PHARMACEUTICALS LTD. is 0.0%. This means that JENBURKT PHARMACEUTICALS LTD. earned ₹0.00 for each ₹1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ JENBURKT PHARMACEUTICALS LTD. = 65,651
Total revenue MRQ JENBURKT PHARMACEUTICALS LTD. = 356,598
₹65,651 / ₹356,598 = 0.00 or 0.0%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient JENBURKT PHARMACEUTICALS LTD. is keeping operating costs low.

Below 1 is considered healthy (always compare to industry mean).
An Operation Ratio of 1.02 means that the operating costs are ₹1.02 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 1.018. The company is inefficient in keeping operating costs low. -1
The TTM is 1.052. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	1.018	TTM	1.052	-0.034
TTM	1.052	YOY	1.077	-0.024
TTM	1.052	5Y	1.047	+0.006
5Y	1.047	10Y	1.047	0.000

Measures how efficient JENBURKT PHARMACEUTICALS LTD. is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of JENBURKT PHARMACEUTICALS LTD. is 101.8%. This means that JENBURKT PHARMACEUTICALS LTD. earned ₹1.02 for each ₹1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(74,548 +290,947) \ 356,598 = 1.02

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of JENBURKT PHARMACEUTICALS LTD..

1.3. Liquidity

1.3.1. Current Ratio

Measures if JENBURKT PHARMACEUTICALS LTD. is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to industry mean).
A Current Ratio of 5.23 means the company has ₹5.23 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 5.227. The company is very able to pay all its short-term debts. +2
The TTM is 5.186. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	5.227	TTM	5.186	+0.041
TTM	5.186	YOY	3.981	+1.205
TTM	5.186	5Y	4.414	+0.772
5Y	4.414	10Y	4.414	0.000

Measures if JENBURKT PHARMACEUTICALS LTD. is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for JENBURKT PHARMACEUTICALS LTD. if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of JENBURKT PHARMACEUTICALS LTD. is 5.23. This means JENBURKT PHARMACEUTICALS LTD. has ₹5.23 in assets for each ₹1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
829,990 \ 158,775) = 5.23

The current ratio measures if JENBURKT PHARMACEUTICALS LTD. is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if JENBURKT PHARMACEUTICALS LTD. is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then JENBURKT PHARMACEUTICALS LTD. does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate JENBURKT PHARMACEUTICALS LTD. is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if JENBURKT PHARMACEUTICALS LTD. is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
A Quick Ratio of 4.25 means the company can pay off ₹4.25 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 4.245. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 4.114. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	4.245	TTM	4.114	+0.131
TTM	4.114	YOY	3.045	+1.069
TTM	4.114	5Y	3.483	+0.632
5Y	3.483	10Y	3.483	0.000

Measures if JENBURKT PHARMACEUTICALS LTD. is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast JENBURKT PHARMACEUTICALS LTD. can pay off its short term debts. This shows if JENBURKT PHARMACEUTICALS LTD. can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of JENBURKT PHARMACEUTICALS LTD. is 4.25. This means that JENBURKT PHARMACEUTICALS LTD. can pay off ₹4.25 for each ₹1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio JENBURKT PHARMACEUTICALS LTD.: (0 + 521,649 +152,401) / 158,775 = 4.25

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of JENBURKT PHARMACEUTICALS LTD..

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of JENBURKT PHARMACEUTICALS LTD. assets are financed with debt.

Below 1 (100%) is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to industry mean.
A Debt to Asset Ratio of 0.13 means that JENBURKT PHARMACEUTICALS LTD. assets are financed with 13.0% credit (debt) and the remaining percentage (100% - 13.0%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 0.130. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.134. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.130	TTM	0.134	-0.003
TTM	0.134	YOY	0.163	-0.029
TTM	0.134	5Y	0.154	-0.021
5Y	0.154	10Y	0.154	0.000

Measures how much % of JENBURKT PHARMACEUTICALS LTD. assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake JENBURKT PHARMACEUTICALS LTD. than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of JENBURKT PHARMACEUTICALS LTD. is 0.13. This means means that JENBURKT PHARMACEUTICALS LTD. is financed with 13.0% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why JENBURKT PHARMACEUTICALS LTD. has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
195,123 \ 1,499,201 = 13.0% or 0.13.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if JENBURKT PHARMACEUTICALS LTD. is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
A Debt to Equity ratio of 15.0% means that company has ₹0.15 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 0.150. The company is very able to pay all its debts with equity. +2
The TTM is 0.154. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.150	TTM	0.154	-0.005
TTM	0.154	YOY	0.195	-0.040
TTM	0.154	5Y	0.183	-0.029
5Y	0.183	10Y	0.183	0.000

Measures if JENBURKT PHARMACEUTICALS LTD. is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of JENBURKT PHARMACEUTICALS LTD. is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of JENBURKT PHARMACEUTICALS LTD. is 0.15. This means that JENBURKT PHARMACEUTICALS LTD. can pay off ₹0.15 for each ₹1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
195,123 \ 1,304,078 = 0.15 or 15.0%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of JENBURKT PHARMACEUTICALS LTD.

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings JENBURKT PHARMACEUTICALS LTD. generates.

Above 15 is considered overpriced but always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
A PE ratio of 10.55 means the investor is paying ₹10.55 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The EOD is 12.074. Based on the earnings, the company is underpriced. +1
The MRQ is 10.554. Based on the earnings, the company is underpriced. +1
The TTM is 11.060. Based on the earnings, the company is underpriced. +1

Trends

Current period		Compared to		+/-
EOD	12.074	MRQ	10.554	+1.520
MRQ	10.554	TTM	11.060	-0.505
TTM	11.060	YOY	13.977	-2.918
TTM	11.060	5Y	11.403	-0.343
5Y	11.403	10Y	11.403	0.000

Measures how much money you pay for each share for every ₹1 in earnings JENBURKT PHARMACEUTICALS LTD. generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare JENBURKT PHARMACEUTICALS LTD. to the industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of JENBURKT PHARMACEUTICALS LTD. is 10.55. This means the investor is paying ₹10.55 for every ₹1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the industry is .
What is the trend?
The trend is important because it shows you how JENBURKT PHARMACEUTICALS LTD. is performing over time. The most recent quarter might be important if JENBURKT PHARMACEUTICALS LTD. released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for JENBURKT PHARMACEUTICALS LTD. up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example JENBURKT PHARMACEUTICALS LTD.

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
\ 4,413 = EPS
PE ratio MRQ = 10.55

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The MRQ is 0.000. The data is not here.

Trends

Current period		Compared to
MRQ	-	TTM	-
TTM	-	YOY	-
TTM	-	5Y	-
5Y	-	10Y	-

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of JENBURKT PHARMACEUTICALS LTD. is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to industry mean).
A PB ratio of 2.37 means the investor is paying ₹2.37 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of JENBURKT PHARMACEUTICALS LTD.:

The EOD is 2.712. Based on the equity, the company is underpriced. +1
The MRQ is 2.370. Based on the equity, the company is underpriced. +1
The TTM is 2.386. Based on the equity, the company is underpriced. +1

Trends

Current period		Compared to		+/-
EOD	2.712	MRQ	2.370	+0.341
MRQ	2.370	TTM	2.386	-0.016
TTM	2.386	YOY	2.109	+0.277
TTM	2.386	5Y	2.210	+0.176
5Y	2.210	10Y	2.210	0.000

2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of JENBURKT PHARMACEUTICALS LTD. compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	18.168	11.868	+53%	18.901	-4%	59.098	-69%	59.098	-69%
Book Value Per Share	-	-	295.488	286.404	+3%	263.761	+12%	266.856	+11%	266.856	+11%
Current Ratio	-	-	5.227	5.186	+1%	3.981	+31%	4.414	+18%	4.414	+18%
Debt To Asset Ratio	-	-	0.130	0.134	-3%	0.163	-20%	0.154	-16%	0.154	-16%
Debt To Equity Ratio	-	-	0.150	0.154	-3%	0.195	-23%	0.183	-18%	0.183	-18%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	16.590	15.494	+7%	11.227	+48%	14.162	+17%	14.162	+17%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Market Cap	-	-	3091075320.000	3015166560.000	+3%	2548596337.850	+21%	2668058879.680	+16%	2668058879.680	+16%
Net Profit Margin	-	-	0.191	0.187	+2%	0.157	+22%	0.183	+5%	0.183	+5%
Operating Margin	-	-	-	-	0%	-	0%	-	0%	-	0%
Operating Ratio	-	-	1.018	1.052	-3%	1.077	-5%	1.047	-3%	1.047	-3%
Pb Ratio	2.712	+13%	2.370	2.386	-1%	2.109	+12%	2.210	+7%	2.210	+7%
Pe Ratio	12.074	+13%	10.554	11.060	-5%	13.977	-24%	11.403	-7%	11.403	-7%
Price Per Share	801.250	+13%	700.400	683.200	+3%	555.325	+26%	591.840	+18%	591.840	+18%
Price To Free Cash Flow Ratio	-	-	-	-	0%	-	0%	-	0%	-	0%
Price To Total Gains Ratio	44.102	+13%	38.551	79.088	-51%	30.004	+28%	44.049	-12%	44.049	-12%
Quick Ratio	-	-	4.245	4.114	+3%	3.045	+39%	3.483	+22%	3.483	+22%
Return On Assets	-	-	0.049	0.047	+4%	0.036	+37%	0.045	+8%	0.045	+8%
Return On Equity	-	-	0.056	0.054	+4%	0.042	+33%	0.053	+5%	0.053	+5%
Total Gains Per Share	-	-	18.168	11.868	+53%	18.901	-4%	59.098	-69%	59.098	-69%
Usd Book Value	-	-	15648936.000	15167850.000	+3%	14526006.000	+8%	14454398.400	+8%	14454398.400	+8%
Usd Book Value Change Per Share	-	-	0.218	0.142	+53%	0.227	-4%	0.709	-69%	0.709	-69%
Usd Book Value Per Share	-	-	3.546	3.437	+3%	3.165	+12%	3.202	+11%	3.202	+11%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	0.199	0.186	+7%	0.135	+48%	0.170	+17%	0.170	+17%
Usd Free Cash Flow	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Market Cap	-	-	37092903.840	36181998.720	+3%	30583156.054	+21%	32016706.556	+16%	32016706.556	+16%
Usd Price Per Share	9.615	+13%	8.405	8.198	+3%	6.664	+26%	7.102	+18%	7.102	+18%
Usd Profit	-	-	878616.000	820536.000	+7%	618300.000	+42%	766824.000	+15%	766824.000	+15%
Usd Revenue	-	-	4594728.000	4372800.000	+5%	3833616.000	+20%	4134768.000	+11%	4134768.000	+11%
Usd Total Gains Per Share	-	-	0.218	0.142	+53%	0.227	-4%	0.709	-69%	0.709	-69%
	EOD	+2 -3	MRQ	TTM	+24 -2	YOY	+20 -6	5Y	+19 -7	10Y	+19 -7

3.2. Fundamental Score

Let's check the fundamental score of JENBURKT PHARMACEUTICALS LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	12.074
Price to Book Ratio (EOD)	Between	0-1	2.712
Net Profit Margin (MRQ)	Greater than	0	0.191
Operating Margin (MRQ)	Greater than	0	0.000
Quick Ratio (MRQ)	Greater than	1	4.245
Current Ratio (MRQ)	Greater than	1	5.227
Debt to Asset Ratio (MRQ)	Less than	1	0.130
Debt to Equity Ratio (MRQ)	Less than	1	0.150
Return on Equity (MRQ)	Greater than	0.15	0.056
Return on Assets (MRQ)	Greater than	0.05	0.049
Total			6/10 (60.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

3.3. Technical Score

Let's check the technical score of JENBURKT PHARMACEUTICALS LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	744.000
Total			0/1 (0.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in INR. All numbers in thousands.

Summary

Total Assets	1,499,201
Total Liabilities	195,123
Total Stockholder Equity	1,304,078

	As reported
Total Liabilities	195,123
Total Stockholder Equity	+ 1,304,078
Total Assets	= 1,499,201

Assets

Total Assets	1,499,201
Total Current Assets	829,990
Long-term Assets	669,209

Total Current Assets

Total Current Assets (as reported)	829,990
Cash And Cash Equivalents	43,232
Short-term Investments	521,649
Net Receivables	152,401
Inventory	97,096
Other Current Assets	10,539
Total Current Assets (calculated)	824,917
+/-	5,073

Long-term Assets

Long-term Assets (as reported)	669,209
Property Plant Equipment	109,022
Intangible Assets	5,738
Long-term Assets Other	208,895
Long-term Assets (calculated)	323,655
+/-	345,554

Liabilities & Shareholders' Equity

Total Current Liabilities	158,775
Long-term Liabilities	36,348
Total Stockholder Equity	1,304,078

Total Current Liabilities

Total Current Liabilities (as reported)	158,775
Short Long Term Debt	136
Accounts payable	72,622
Other Current Liabilities	16,379
Total Current Liabilities (calculated)	89,137
+/-	69,638

Long-term Liabilities

Long-term Liabilities (as reported)	36,348
Capital Lease Obligations Min Short Term Debt	2,492
Long-term Liabilities (calculated)	2,492
+/-	33,856

Total Stockholder Equity

Total Stockholder Equity (as reported)	1,304,078
Total Stockholder Equity (calculated)	0
+/-	1,304,078

Other

Capital Stock	44,133
Common Stock Shares Outstanding	4,413
Net Invested Capital	1,304,214
Net Working Capital	671,215
Property Plant and Equipment Gross	109,022

Balance Sheet

Currency in INR. All numbers in thousands.

Trend

2023-09-30

2023-03-31

2022-09-30

2022-03-31

2021-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

> Total Assets

0
0
0
0
1,308,892
1,429,491
1,460,864
1,418,121
1,499,201

1,499,201

1,418,121

1,460,864

1,429,491

1,308,892

> Total Current Assets

875,187
0
895,427
0
738,327
759,042
765,646
810,906
829,990

829,990

810,906

765,646

759,042

738,327

895,427

875,187

Cash And Cash Equivalents

0
0
0
0
34,822
50,314
36,156
36,599
43,232

43,232

36,599

36,156

50,314

34,822

Short-term Investments

0
0
0
0
459,139
415,545
454,937
458,245
521,649

521,649

458,245

454,937

415,545

459,139

Net Receivables

188,020
0
222,801
0
152,502
152,068
141,236
169,616
152,401

152,401

169,616

141,236

152,068

152,502

222,801

188,020

Inventory

114,627
0
108,987
0
79,269
98,877
114,609
83,376
97,096

97,096

83,376

114,609

98,877

79,269

108,987

114,627

Other Current Assets

11,348
0
13,304
0
8,725
60
12,401
1,379
10,539

10,539

1,379

12,401

8,725

13,304

11,348

> Long-term Assets

0
0
0
0
570,566
670,449
695,218
607,214
669,209

669,209

607,214

695,218

670,449

570,566

Property Plant Equipment

89,333
0
110,032
0
0
0
110,113
227,101
109,022

109,022

227,101

110,113

110,032

89,333

Goodwill

0
0
0
0
14
0
0
0
0

Intangible Assets

0
0
0
0
3,717
3,056
2,629
1,874
5,738

5,738

1,874

2,629

3,056

3,717

Long-term Assets Other

0
0
0
0
1,314
113,097
119,636
120,233
208,895

208,895

120,233

119,636

113,097

1,314

> Total Liabilities

0
0
0
0
235,202
255,666
213,688
194,224
195,123

195,123

194,224

213,688

255,666

235,202

> Total Current Liabilities

213,664
0
198,008
0
197,650
212,798
174,174
157,619
158,775

158,775

157,619

174,174

212,798

197,650

198,008

213,664

Short Long Term Debt

0
0
0
0
27,216
58,152
15,824
24,411
136

136

24,411

15,824

58,152

27,216

Accounts payable

68,016
0
52,264
0
62,422
71,104
75,161
60,968
72,622

72,622

60,968

75,161

71,104

62,422

52,264

68,016

Other Current Liabilities

93,745
0
85,778
0
19,451
11,522
19,364
11,477
16,379

16,379

11,477

19,364

11,522

19,451

85,778

93,745

> Long-term Liabilities

0
0
0
0
37,552
42,868
39,514
36,605
36,348

36,348

36,605

39,514

42,868

37,552

Capital Lease Obligations Min Short Term Debt

0
0
0
0
11,521
9,397
7,187
4,886
2,492

2,492

4,886

7,187

9,397

11,521

> Total Stockholder Equity

0
0
0
0
1,073,690
1,173,825
1,247,176
1,223,897
1,304,078

1,304,078

1,223,897

1,247,176

1,173,825

1,073,690

Retained Earnings

0
0
777,545
0
0
1,085,268
0
1,131,050
0

1,131,050

1,085,268

777,545

Accumulated Other Comprehensive Income

Capital Surplus

Treasury Stock

Balance Sheet

Currency in INR. All numbers in thousands.

	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31
Accounts Payable	60,968	71,104	45,924	52,264	65,490	41,221	60,162
Accumulated Amortization	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	0	0	0	0	0	0	0
Additional Paid In Capital	0	0	0	0	0	0	0
Capital Lease Obligations	4,886	9,397	13,563	17,409	0	0	0
Capital Stock	44,133	45,894	45,894	45,894	45,894	0	0
Capital Surpluse	0	0	0	0	0	0	0
Cash	36,599	50,314	24,937	25,340	12,268	0	0
Cash And Equivalents	0	0	0	0	0	0	0
Cash And Short Term Investments	0	0	0	0	0	0	0
Common Stock	0	0	0	45,894	45,894	46,493	46,493
Common Stock Shares Outstanding	4,413	4,589	4,589	4,589	4,589	0	0
Common Stock Total Equity	0	0	0	0	0	0	0
Current Deferred Revenue	0	0	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0
Good Will	0	0	14	14	14	0	0
Intangible Assets	1,874	3,056	4,797	8,414	11,490	0	0
Inventory	83,376	98,877	75,815	108,987	98,312	68,044	107,457
Liabilities And Stockholders Equity	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0
Long Term Debt Total	0	0	0	0	0	0	0
Long Term Investments	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0
Net Debt	0	7,838	12,169	9,049	62,425	0	0
Net Invested Capital	1,248,308	1,231,977	1,021,769	834,432	849,348	0	0
Net Receivables	169,616	152,068	140,007	222,801	256,457	147,670	119,366
Net Tangible Assets	0	0	0	791,616	773,052	611,410	543,084
Net Working Capital	653,287	546,244	619,954	697,420	670,525	528,522	455,902
Non Current Assets Total	607,214	670,450	411,961	145,272	131,570	0	0
Non Current Liabilities Other	-1	0	-1	29,084	27,440	0	0
Non Current Liabilities Total	36,605	42,868	47,249	42,647	27,440	0	0
Non Currrent Assets Other	120,233	113,097	910	0	0	0	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0
Other Assets	0	0	0	1,845	7,189	3,533	5,050
Other Current Assets	1,379	60	11,692	13,304	13,767	28,226	8,411
Other Current Liab	11,477	11,522	10,640	85,778	77,743	83,376	54,394
Other Liab	0	0	0	29,084	27,438	29,058	34,301
Other Stockholder Equity	0	0	0	-23,396	1,142	518	7,404
Preferred Stock Redeemable	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0
Property Plant And Equipment Gross	446,950	430,671	303,924	295,078	0	0	0
Property Plant And Equipment Net	227,101	224,053	104,468	110,033	0	0	0
Property Plant Equipment	0	0	0	110,032	104,216	94,491	104,981
Retained Earnings	1,131,050	1,085,268	909,107	777,545	727,619	566,191	490,470
Retained Earnings Total Equity	0	0	0	0	0	0	0
Short Long Term Debt	24,411	58,152	37,106	34,389	74,693	0	0
Short Long Term Debt Total	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0
Short Term Investments	458,245	415,545	495,137	520,179	510,977	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0
Total Assets	1,418,121	1,429,491	1,211,831	1,040,698	1,028,249	0	0
Total Current Assets	810,906	759,042	799,873	895,427	896,680	659,216	638,859
Total Current Liabilities	157,619	212,798	179,919	198,008	226,156	130,694	182,957
Total Liab	194,224	255,666	227,168	240,655	253,594	0	0
Total Permanent Equity	0	0	0	0	0	0	0
Total Stockholder Equity	1,223,897	1,173,825	984,663	800,043	774,655	0	0
Treasury Stock	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0

	2023-09-30	2023-03-31	2022-09-30	2022-03-31	2021-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30
Accounts Payable	72,622	60,968	75,161	71,104	62,422	0	52,264	0	68,016
Accumulated Amortization	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	2,492	4,886	7,187	9,397	11,521	0	0	0	0
Capital Stock	44,133	44,133	45,894	45,894	45,894	0	0	0	0
Capital Surpluse	0	0	0	0	0	0	0	0	0
Cash	43,232	36,599	36,156	50,314	34,822	0	0	0	0
Cash And Equivalents	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	0	0	0	0	0	0	0	0	0
Common Stock	0	0	0	0	0	0	45,894	0	45,894
Common Stock Shares Outstanding	4,413	4,413	4,589	4,589	4,589	0	0	0	0
Common Stock Total Equity	0	0	0	0	0	0	0	0	0
Current Deferred Revenue	0	0	0	0	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0
Good Will	0	0	0	0	14	0	0	0	0
Intangible Assets	5,738	1,874	2,629	3,056	3,717	0	0	0	0
Inventory	97,096	83,376	114,609	98,877	79,269	0	108,987	0	114,627
Liabilities And Stockholders Equity	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0
Long Term Debt Total	0	0	0	0	0	0	0	0	0
Long Term Investments	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0
Net Debt	0	0	0	7,838	0	0	0	0	0
Net Invested Capital	1,304,214	1,248,308	1,263,000	1,231,977	1,100,906	0	0	0	0
Net Receivables	152,401	169,616	141,236	152,068	152,502	0	222,801	0	188,020
Net Tangible Assets	0	0	0	0	0	791,616	791,616	746,398	746,398
Net Working Capital	671,215	653,287	591,472	546,244	540,677	0	697,419	0	661,523
Non Current Assets Total	669,209	607,214	695,218	670,449	570,566	0	0	0	0
Non Current Liabilities Other	0	-1	0	0	-2	0	0	0	0
Non Current Liabilities Total	36,348	36,605	39,514	42,868	37,552	0	0	0	0
Non Currrent Assets Other	208,895	120,233	119,636	113,097	1,314	0	0	0	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0
Other Assets	0	0	0	0	0	0	1,845	0	4,238
Other Current Assets	10,539	1,379	12,401	60	8,725	0	13,304	0	11,348
Other Current Liab	16,379	11,477	19,364	11,522	19,451	0	85,778	0	93,745
Other Liab	0	0	0	0	0	0	29,084	0	28,138
Other Stockholder Equity	0	0	0	0	0	0	-23,396	0	728,736
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	109,022	446,950	110,113	0	0	0	0	0	0
Property Plant And Equipment Net	109,022	227,101	110,113	0	0	0	0	0	0
Property Plant Equipment	0	0	0	0	0	0	110,032	0	89,333
Retained Earnings	0	1,131,050	0	1,085,268	0	0	777,545	0	0
Retained Earnings Total Equity	0	0	0	0	0	0	0	0	0
Short Long Term Debt	136	24,411	15,824	58,152	27,216	0	0	0	0
Short Long Term Debt Total	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0
Short Term Investments	521,649	458,245	454,937	415,545	459,139	0	0	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0
Total Assets	1,499,201	1,418,121	1,460,864	1,429,491	1,308,892	0	0	0	0
Total Current Assets	829,990	810,906	765,646	759,042	738,327	0	895,427	0	875,187
Total Current Liabilities	158,775	157,619	174,174	212,798	197,650	0	198,008	0	213,664
Total Liab	195,123	194,224	213,688	255,666	235,202	0	0	0	0
Total Permanent Equity	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	1,304,078	1,223,897	1,247,176	1,173,825	1,073,690	0	0	0	0
Treasury Stock	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0

Cash Flow

Currency in INR. All numbers in thousands.

	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31
Begin Period Cash Flow	50,313	24,937	25,340	12,268	11,837	0	0
Capital Expenditures	21,045	30,543	11,451	45,544	24,014	4,535	3,724
Cash And Cash Equivalents Changes	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	0	0	0	0	0
Change In Cash	-13,714	25,376	-403	13,072	431	-8,029	8,610
Change In Working Capital	-60,502	-107,907	52,507	5,679	-49,011	72,620	0
Change Receivables	0	0	0	0	0	0	0
Change To Account Receivables	0	0	0	50,651	-103,605	-29,184	-33,329
Change To Inventory	15,500	-23,062	33,172	-10,675	-30,268	39,413	-25,072
Change To Liabilities	0	0	0	-13,225	24,269	-18,941	27,136
Change To Netincome	0	0	0	-27,200	-32,631	-35,017	-23,313
Change To Operating Activities	0	0	0	-21,072	60,594	18,443	1,145
Depreciation	22,591	18,986	20,354	17,663	13,389	14,728	17,599
Dividends Paid	54,997	46,804	0	85,819	14,600	66,144	66,144
End Period Cash Flow	36,599	50,313	24,937	25,340	12,268	11,837	0
Exchange Rate Changes	0	0	0	0	0	0	0
Free Cash Flow	149,475	62,171	183,097	104,624	105,854	157,303	95,791
Investments	26,179	-12,024	-187,810	-15,607	-110,226	-20,295	-122,482
Issuance Of Capital Stock	0	0	0	0	0	0	0
Net Borrowings	0	0	0	0	-53	-61,336	9,558
Net Income	246,070	222,972	165,024	148,696	197,978	172,122	135,076
Other Cashflows From Financing Activities	0	0	0	-22,520	-9,520	-51,766	-2,795
Other Cashflows From Investing Activities	0	0	0	22,484	28,976	34,639	26,709
Other Non Cash Items	-36,308	-39,177	-35,858	-31,097	-28,191	0	0
Sale Purchase Of Stock	-145,151	0	0	0	0	0	0
Stock Based Compensation	0	0	0	0	0	0	0
Total Cash From Financing Activities	0	0	0	-108,339	-24,173	-179,845	6,763
Total Cash From Operating Activities	170,520	92,714	194,548	150,168	129,868	161,838	99,515
Total Cashflows From Investing Activities	0	0	0	-28,757	-105,264	9,978	-97,668

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30
Begin Period Cash Flow	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Capital Expenditures	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Cash Equivalents Changes	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Cash Flows Other Operating	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Change In Cash	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Change In Working Capital	-	17,928	-	61,815	-	45,228	-	5,567	-	0	0	0	0	0
Change Receivables	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Change To Account Receivables	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Change To Inventory	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Change To Liabilities	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Change To Netincome	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Change To Operating Activities	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Depreciation	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Dividends Paid	-	0	-	0	-	0	-	0	-	0	0	0	0	0
End Period Cash Flow	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Exchange Rate Changes	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Free Cash Flow	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Investments	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Issuance Of Capital Stock	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Net Borrowings	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Net Income	54,044	73,218	53,691	63,538	54,338	68,562	59,532	34,488	62,271	79,704	10,080	46,164	46,388	55,525
Other Cashflows From Financing Activities	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Other Cashflows From Investing Activities	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Other Non Cash Items	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Sale Purchase Of Stock	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Stock Based Compensation	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Total Cash From Financing Activities	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Total Cash From Operating Activities	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Total Cashflows From Investing Activities	-	0	-	0	-	0	-	0	-	0	0	0	0	0

Income Statement

Currency in INR. All numbers in thousands.

	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31	2017-03-31
Cost Of Revenue	338,055	320,627	304,430	335,837	370,593	0	0
Depreciation And Amortization	0	0	0	0	0	0	0
Discontinued Operations	0	0	0	0	0	0	0
Ebit	0	0	0	174,470	236,241	223,318	179,713
Ebitda	354,908	321,175	241,012	239,312	283,382	0	0
Effect Of Accounting Charges	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0
Gross Profit	1,023,350	916,690	784,254	853,072	855,850	0	0
Income Before Tax	328,647	298,709	216,417	211,378	266,334	0	0
Income Tax Expense	0	0	0	62,682	68,356	80,567	69,713
Interest Expense	2,997	3,480	4,241	4,941	3,517	0	0
Interest Income	40,199	43,714	40,525	36,353	32,049	0	0
Minority Interest	0	0	0	0	0	0	0
Net Income	246,070	222,972	165,024	148,696	197,978	0	0
Net Income Applicable To Common Shares	0	0	0	148,696	197,978	172,122	135,086
Net Income From Continuing Ops	246,070	222,972	165,024	148,696	197,978	0	0
Net Interest Income	36,529	39,370	35,788	31,096	28,190	0	0
Non Operating Income Net Other	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0
Operating Income	281,128	253,585	178,085	174,470	236,240	0	0
Other Items	0	0	0	0	0	0	0
Other Operating Expenses	0	0	0	288,792	297,632	285,609	273,468
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0
Reconciled Depreciation	22,591	18,986	20,354	22,993	13,531	0	0
Research Development	12,259	10,806	9,848	9,254	1,000	0	0
Selling And Marketing Expenses	0	0	0	0	0	0	0
Selling General Administrative	234,716	206,526	218,664	207,064	201,023	0	0
Tax Provision	82,577	75,737	51,393	62,682	68,356	0	0
Total Operating Expenses	1,080,277	983,732	910,599	1,014,439	990,203	0	0
Total Other Income Expense Net	0	0	0	0	0	0	0
Total Revenue	1,361,405	1,237,317	1,088,684	1,188,909	1,226,443	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30
Cost Of Revenue	74,548	92,048	55,423	99,152	81,050	86,413	71,441	79,691	80,454	89,691	0	0	0	0
Depreciation And Amortization	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Discontinued Operations	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Ebit	-	0	-	0	-	0	-	0	-	0	1,332	57,254	59,818	68,878
Ebitda	-	0	80,041	87,540	84,445	98,772	84,150	58,447	82,586	114,591	0	0	0	0
Effect Of Accounting Charges	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Extraordinary Items	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Gross Profit	282,050	290,846	236,329	246,754	264,608	272,109	239,878	200,723	249,567	265,393	0	0	0	0
Income Before Tax	78,404	95,404	74,301	80,758	77,570	92,388	77,931	52,718	76,848	108,965	0	0	0	0
Income Tax Expense	-	0	-	0	-	0	-	0	-	0	-104	22,727	20,332	20,016
Interest Expense	703	686	738	165	1,031	935	865	348	1,009	1,091	0	0	0	0
Interest Income	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Minority Interest	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Net Income	54,044	73,218	53,691	63,538	54,338	68,562	59,532	34,488	62,271	79,704	0	0	0	0
Net Income Applicable To Common Shares	-	0	-	0	-	0	-	0	-	0	10,080	46,164	46,388	55,525
Net Income From Continuing Ops	54,044	73,218	53,691	63,538	54,338	68,662	59,532	34,488	62,271	79,704	0	0	0	0
Net Interest Income	-703	-686	-738	39,361	-1,031	-935	-865	42,502	-1,009	-1,091	0	0	0	0
Non Operating Income Net Other	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Non Recurring	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Operating Income	65,651	85,135	64,667	69,084	63,964	80,709	67,370	41,167	65,007	98,150	0	0	0	0
Other Items	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Other Operating Expenses	-	0	-	0	-	0	-	0	-	0	44,515	64,241	85,645	79,806
Preferred Stock And Other Adjustments	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Reconciled Depreciation	6,296	5,913	5,002	5,944	5,844	5,449	5,354	5,381	4,729	4,535	0	0	0	0
Research Development	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Selling And Marketing Expenses	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Selling General Administrative	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Tax Provision	24,360	22,186	20,610	17,220	23,232	23,726	18,399	18,230	14,577	29,261	0	0	0	0
Total Operating Expenses	290,947	297,759	227,085	276,822	281,694	277,813	243,949	239,247	265,014	256,934	0	0	0	0
Total Other Income Expense Net	-	0	-	0	-	0	-	0	-	0	0	0	0	0
Total Revenue	356,598	382,894	291,752	345,906	345,658	358,522	311,319	280,414	330,021	355,084	0	0	0	0

Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue	1,361,405
Cost of Revenue	-338,055
Gross Profit	1,023,350	1,023,350

Operating Income (+$)
Gross Profit	1,023,350
Operating Expense	-1,080,277
Operating Income	281,128	-56,927

Operating Expense (+$)
Research Development	12,259
Selling General Administrative	234,716
Selling And Marketing Expenses	0
Operating Expense	1,080,277	246,975

Net Interest Income (+$)
Interest Income	40,199
Interest Expense	-2,997
Other Finance Cost	-673
Net Interest Income	36,529

Pretax Income (+$)
Operating Income	281,128
Net Interest Income	36,529
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	328,647	281,128 EBIT - interestExpense = -2,997 246,070 249,067
Interest Expense	2,997
Earnings Before Interest and Taxes (EBIT)	0	331,644
Earnings Before Interest and Taxes (EBITDA)	354,908

After tax Income (+$)
Income Before Tax	328,647
Tax Provision	-82,577
Net Income From Continuing Ops	246,070	246,070
Net Income	246,070
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	0
Total Other Income/Expenses Net	0	-36,529

Technical Analysis of JENBURKT PHARMACEUTICALS LTD.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of JENBURKT PHARMACEUTICALS LTD.. The general trend of JENBURKT PHARMACEUTICALS LTD. is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine JENBURKT PHARMACEUTICALS LTD.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator State	Bullish trend		Bearish trend
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of JENBURKT PHARMACEUTICALS LTD..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 809.00 < 814.00 < 836.60.

The bearish price targets are: 706.35 > 665.00 > 660.05.

Tweet this

JENBURKT PHARMACEUTICALS LTD. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of JENBURKT PHARMACEUTICALS LTD.. The current mas is .

Directionalities and relatives.

Moving Average	Amount of candles	Trend	Price +/-	vs. MA 50	vs. MA 100	vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

JENBURKT PHARMACEUTICALS LTD. Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of JENBURKT PHARMACEUTICALS LTD.. The current adx is .

JENBURKT PHARMACEUTICALS LTD. Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of JENBURKT PHARMACEUTICALS LTD..

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

JENBURKT PHARMACEUTICALS LTD. Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for JENBURKT PHARMACEUTICALS LTD..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2023-12-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-11	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-12	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-20	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2023-12-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-22	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-28	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-29	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-01-01	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-03	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-01-04	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-01-11	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-01-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-18	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-19	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-01-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-23	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-01-24	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-29	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-31	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-01	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-02-02	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-02-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-06	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-07	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-02-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-02-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-19	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-02-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-28	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-29	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-04	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-03-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-06	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-07	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-03-11	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-15	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
2024-03-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-22	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-01	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-02	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-03	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-04-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-10	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-12	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-04-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-16	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-19	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-24	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-25	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-30	STOCH	LONG EXIT		The %K line crosses below the %D line.

6.3. Candlestick Patterns

JENBURKT PHARMACEUTICALS LTD. Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of JENBURKT PHARMACEUTICALS LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	744.000
Total			0/1 (0.0%)

Create your own Symbol Scanner

Get notifications about JENBURKT PHARMACEUTICALS LTD.

I send you an email if I find something interesting about JENBURKT PHARMACEUTICALS LTD..

JENBURKT PHARMACEUTICALS LTD. Buy, Hold or Sell?

Let's analyse JENBURKT PHARMACEUTICALS LTD. together

Get notifications about JENBURKT PHARMACEUTICALS LTD.

Quick analysis of JENBURKT PHARMACEUTICALS LTD. (30 sec.)

What can you expect buying and holding a share of JENBURKT PHARMACEUTICALS LTD.? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of JENBURKT PHARMACEUTICALS LTD. (5 min.)

INR801.25

INR295.49

2. Growth of JENBURKT PHARMACEUTICALS LTD. (5 min.)

Is JENBURKT PHARMACEUTICALS LTD. growing?

How much money is JENBURKT PHARMACEUTICALS LTD. making?

How much money comes from the company's main activities?

3. Financial Health of JENBURKT PHARMACEUTICALS LTD. (5 min.)

What can you expect buying and holding a share of JENBURKT PHARMACEUTICALS LTD.? (5 min.)

What can you expect buying and holding a share of JENBURKT PHARMACEUTICALS LTD.?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of JENBURKT PHARMACEUTICALS LTD.

About JENBURKT PHARMACEUTICALS LTD.

Financial Health

Valuation

1.1. Profitability of JENBURKT PHARMACEUTICALS LTD..

1.1. Profitability

1.1.1. Net Profit Margin

Trends

1.1.2. Return on Assets

Trends

1.1.3. Return on Equity

Trends

1.2. Operating Efficiency of JENBURKT PHARMACEUTICALS LTD..

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

1.2.2. Operating Ratio

Trends

1.3. Liquidity of JENBURKT PHARMACEUTICALS LTD..

1.3. Liquidity

1.3.1. Current Ratio

Trends

1.3.2. Quick Ratio

Trends

1.4. Solvency of JENBURKT PHARMACEUTICALS LTD..

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

1.4.2. Debt to Equity Ratio

Trends

2. Market Valuation of JENBURKT PHARMACEUTICALS LTD.

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

2.2. Price To Free Cash Flow Ratio

Trends

2. Book Value per Share

2.3. Price to Book Ratio

Trends

JENBURKT PHARMACEUTICALS LTD.
Buy, Hold or Sell?